The present invention is directed to a crystalline compound comprising a hydrobromide acid (HBr) salt of a compound of formula (I) (1 {2 [(2 4 dimethylphenyl)sulfanyl]phenyl}piperazine INN: vortioxetine) having an XRPD pattern with characteristic peaks (expressed in 2 � 0 2� 2 (CuKa radiation)) at 5.5� 14.8� 16.7� and 20.0� and processes for obtaining the same.